Jacques Dumas
Jacques Dumas joined Aicuris in 2024, bringing over 30 years of experience in pharmaceutical R&D across infectious diseases and oncology. Jacques has a proven track record of driving novel medicines from discovery to launch, including non-clinical development and CMC.
He previously served as Chief Scientific Officer at Arrakis Therapeutics, leading R&D efforts and scaling the organisation to support collaborations with Roche and Amgen. Prior to that, he was Chief Scientific Officer at Tetraphase (2015-2019) and Idenix (2014), two biotech companies in the anti-infective space. Early in his career, Jacques spent 15 years at Bayer Healthcare and seven years at AstraZeneca.
ArticleAdvancing antiviral therapeutics for immunocompromised populations
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.